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OBJECTIVES: To provide a comprehensive overview of existing
literature on inguinal, ventral, and umbilical hernias in the UK,
US, France, Germany, and Italy in four independent areas: 1) epi-
demiology; 2) treatment guidelines and management; 3) health-
related quality of life; and 4) economic burden. METHODS:
Systematic reviews and meta-analyses were reviewed ahead of
any single studies. Studies included in the systematic reviews
were not reviewed independently. Where systematic reviews were
not available, the next highest level of evidence was identiﬁed.
RESULTS: Seven studies examining incidence of inguinal (5),
ventral (2), and umbilical hernia (0); 17 studies of HRQL in
inguinal hernia repair (none in ventral or umbilical hernia
repair); 4 systematic reviews and 22 costing studies of inguinal
hernia repair (4 ventral hernia costing studies; none for umbili-
cal); and 10 published guidelines on inguinal hernia repair only
(none for France, Italy, or Germany) were identiﬁed. No preva-
lence studies were found and incidence data was limited to hernia
repair procedures and recurrences versus true incidence of
hernia. Open mesh repair appears most common due to safety,
ease of technique, low recurrence rates and cost although laparo-
scopic repair has potential beneﬁts over open mesh. Hernia
repair generally leads to improved HRQL regardless of surgical
technique. Mixed evidence supports LH patients having better
HRQL, post-operative pain outcomes, return to work and usual
daily activities proﬁle following inguinal hernia surgery than OH
patients. The inclusion of indirect costs such as absenteeism and
presenteeism can signiﬁcantly reduce or eliminate cost differ-
ences between laparoscopic and open repair as noted in TEP pro-
cedures. CONCLUSIONS: Although hernia repair is a common
procedure, its epidemiology, treatment guidelines and manage-
ment recommendations are not well referenced in the literature.
Evidence based decision-making would be improved through
reporting of real world, observational, longitudinal hernia repair
data.
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CLINICAL EFFECTIVENESS OF ADJUSTABLE DOSING SINGLE
INHALER BUDESONIDE/FORMOTEROL FOR ASTHMA AND
BUDGET IMPACT ANALYSIS
Kaczor M, Becla L,Wojcik R, Dardzinski W, Walczak J, Nogas G
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OBJECTIVES: To compare budesonide/formoterol in single
inhaler with budesonide + formoterol from separate inhalers and
adjustable dosing of single inhaler budesonide/formoterol with
ﬁxed dosing in patients with moderate and severe persistent
asthma. To assess national payers budget impact. METHODS:
The clinical effectiveness analysis was performed according to
Cochrane Collaboration Guidelines. Budget impact model
consist of 3 refund settings scenarios for single inhaler, adjustable
dosing budesonide/formoterol. RESULTS: Budesonide/for-
moterol in single inhaler vs budesonide + formoterol from sepa-
rate inhalers Three RTC were included. No signiﬁcant difference
in quality of life and others parameters of disease symptoms
control. Only dysphonia presence was statistically lower in single
inhaler group (I 3 months follow-up), OR = 0.12 (0.02; 0.88).
Fixed dosing versus adjustable dosing 7 RTC were included. No
signiﬁcant difference in quality of life and number of patients
with at least one disease exacerbation (three months follow-up).
Metaanalysis of trials with 5–6 months follow-up showed lower
disease exacerbation risk with adjustable dosing, RR = 0.56
(0.40; 0.77). No signiﬁcant difference in frequency of severe
disease exacerbation, multiple exacerbation of disease, necessity
of oral administration of corticosteroids and additional therapy.
Lower risk of hospitalization/emergency treatment with
adjustable dosing, RR = 0.65 (0.43; 0.98) was observed. Both
treatments were well tolerated but the adverse event proﬁle was
statistically lower in adjustable dosing—less sever, asthma
related adverse events, OR = 0.12 (0.02; 0.72) in three months
follow-up was noticed. Budget impact model Single inhaler
budesonide/formoterol refund consequences per year: 0.4 million
sold drug units; 3248 avoided medical visits; 518 avoided hos-
pital/emergency asthma exacerbations treatments; 27.7% reduc-
tion in drugs intake volumen; 11–32 millions PLN national
insurer budget savings. CONCLUSIONS: Single inhaler budes-
onide/formoterol therapy, especially adjustable dosing, is a clin-
ically effective and well-tolerated treatment for patients with
asthma. Refund of this therapy may generate savings for national
insurer budget.
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OBJECTIVES: Efﬁcacy of sublingual-immunotherapy (SLIT) has
been assessed by several studies and conﬁrmed by the WHO
ARIA paper and Cochrane review. Effect of SLIT on consump-
tion of medical resources is yet to be proven in a naturalistic
environment. METHODS: A network of specialist allergy
centres provided data on access to medical care for patients
affected by allergic rhinitis (R) with or without asthma (A)
enrolled in February 2004. Patients affected by grass pollen
allergy, documented by allergen tests, were included in this analy-
sis and split into SLIT patients and patients treated with symp-
tomatic drugs (controls). Outcome measures included use of
medications, SLIT, routine care visits, other specialist visits, hos-
pital admissions and tests. Costs were assessed from the per-
spective of the Italian NHS; unit costs were obtained from
published sources (national tariffs for visits and tests; market
prices for drugs and immunotherapies). Average cost/patient for
the ﬁrst year after enrolment was produced. RESULTS: One-
hundred and two patients were analyzed (SLIT/Controls 54/48;
M/F 56/46; mean age 30 + 13 years; mean follow-up 376 + 29
days). Demographics were comparable in the two groups.
Overall per patient yearly cost of treatment was higher in SLIT
patients, in the whole sample (€311 vs. €180/patient), in the R
(€288 vs. €116) and R + A (€362 vs. €230) subpopulations, with
R + A patients generating more costs than R patients in both
groups. Nevertheless considerable savings were obtained in the
